Oncology ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B... Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.
News Takeda builds in cancer with monster $11.4bn Innovent deal Takeda has partnered with China's Innovent for a pair of late-stage cancer therapies, in a deal that includes an upfront payment of $1.2bn.
Oncology ASCO 2024 – Thanos Zomas Great advances in cancer care have led to a new phase of research in certain cancers – in areas where a high rate of cure has been established, the focus is shifting to quality of life, sid
Views & Analysis Cutting the combination therapy access issue down to size While the access to combination treatments problem is nothing new, its sheer magnitude means it has, to date, gone unsolved.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.